



LAO PEOPLE 'S DEMOCRATIC REPUBLIC
PEACE INDEPENDENCE DEMOCRACY UNITY PROSPERITY

MINISTRY OF HEALTH
FOOD AND DRUG DEPARTMENT
TEL (856 21) 214013, 214014
FAX: (856 21) 214015.

Certificate of Drug Registration

Registration Number:07-LM-10047-26

ALI-LENA

Dosage Form	INJECTION
Active Ingredients	LENACAPAVIR SODIUM 473.1 mg
Description	Lenacapavir is supplied as a 463.5mg/1.5mL injectable solution in a glass vial, for subcutaneous use, packaged in a carton with leaflet.Packaging size: 1.5 mL per vial, 2 vials per box. Dosage form: The injection solution is sterile, preservative-free, clear, and yellow with no visible particles.This product is clear liquid ranging from light yellow to yellow.
Size of packaging unit	2 vials
Indications	See Annex
Manufacturer	ALLIANCE PHARMACEUTICAL CO.,LTD SIMMANONEUA VILLAGE, HADSAYFONG DISTRICT, VIENTIANE CAPITAL, LAO PDR

This Certificate is issued to attest that the product described above has met the minimum standards required for drug registration undertaken by the Food and Drug Department in Lao PDR.

This certificate expires, unless previously suspended or revoked, on 15 July 2031

Note: All boxes and packaging for importations must bear the Lao Registration No. 07-LM-10047-26

At, Vientiane, 15 July 2026



ນ.ພຸດທະວັນ ອິນລິຄາ



Registration Number:07-LM-10047-26

ALI-LENA

ANNEX

INDICATIONS

Lenacapavir, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations.

Lenacapavir ແມ່ນຢາຕ້ານ capsid ຂອງໄວຣັສ HIV-1 ທີ່ໃຊ້ຮ່ວມກັບຢາຕ້ານໄວຣັສຊະນິດອື່ນໆ ມີຂໍ້ບັງໃຊ້ໃນການຮັກສາການຕິດເຊື້ອ HIV-1 ໃນຄົນເຈັບຜູ້ໃຫຍ່ທີ່ເຄີຍຜ່ານການປິ່ນປົວດ້ວຍຢາມາຫຼາຍແລ້ວ ແຕ່ບໍ່ໄດ້ຜົນ ແລະ ມີການຕ້ານຕໍ່ຢາຫຼາຍຊະນິດ ຢາຕ້ານໄວຣັສທີ່ໃຊ້ໃນປະຈຸບັນບໍ່ໄດ້ຜົນເນື່ອງຈາກບັນຫາການຕ້ານຕໍ່ຢາ, ການແພ້ຢາ ຫຼື ປັນຫາຄວາມປອດໄພໃນການໃຊ້ຢາ.